OBJECTIVEWe investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D).RESEARCH DESIGN AND METHODSA total of 732 recently diagnosed patients with T2D from the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) study were extensively phenotyped over 3 years, including measures of insulin sensitivity (OGIS), beta-cell glucose sensitivity (GS), and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA(1c) deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression.RESUL...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...
Aims/hypothesis: There is considerable variability in how diabetes progresses after diagnosis. Progr...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
Objective We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Objective: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
OBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a Europea...
Aims/hypothesisThe DIRECT (Diabetes Research on Patient Stratification) Study is part of a European ...
Aim: Subclasses of different glycaemic disturbances could explain the variation in characteristics o...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
AimsThe two predominant pathophysiological defects resulting in glucose intolerance are beta-cell dy...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...
Aims/hypothesis: There is considerable variability in how diabetes progresses after diagnosis. Progr...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
Objective We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Objective: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
OBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a Europea...
Aims/hypothesisThe DIRECT (Diabetes Research on Patient Stratification) Study is part of a European ...
Aim: Subclasses of different glycaemic disturbances could explain the variation in characteristics o...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
AimsThe two predominant pathophysiological defects resulting in glucose intolerance are beta-cell dy...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...
Aims/hypothesis: There is considerable variability in how diabetes progresses after diagnosis. Progr...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...